Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American

Completed

• Conditions: Kidney Neoplasms

• Registration Number: NCT05184504
• Lead Sponsor: Latin American Cooperative Oncology Group

Brief Summary

Observational study, retrospective and prospective, of an analytical nature. Data will be collected from medical records and/or through contact with physicians and institutions (secondary data collection). Patients included retrospectively or prospectively will be followed during the data collection period for the evaluation of treatments and survival. No intervention is planned in this protocol.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-12-20
• Study First Submitted QC: 2022-01-07
• Study First Posted: 2022-01-11
• Study Start: 2022-09-01
• Primary Completion: 2024-07-11
• Study Completion: 2024-07-11
• Status Verified: 2025-02
• Last Update Submitted: 2025-02-11
• Last Update Posted: 2025-02-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 211

Inclusion Criteria

• Patients ≥ 18 years of age;
• Proven histology of renal cell carcinoma (any subtype);
• Pathological diagnosis of renal cell carcinoma in January 2015 or later and new cases diagnosed during the period of recruitment of each center;
• Have the medical record available and suitable for collecting data on patient characteristics, treatment and outcome.

Exclusion Criteria

• Synchronous or other primary tumor within the last 3 years (except thyroid cancer or non melanoma skin).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Build a real-life renal cell cancer database in Brazil and Latin America	2022

Secondary Outcome Measures

Name	Time	Method
Progression-free survival in each therapeutic line	2022
Causes of delay or discontinuation of each treatment checklist	2022	Characteristics of systemic treatment
Time between diagnosis and start of treatment.	2022	Characteristics of systemic treatment checklist
Overall survival	2022
Clinicopathological characteristics of patients with renal cell cancer checklist	2022	date of onset of symptoms, pre-treatment symptoms, histology, clinical and pathological stage, performance status, tests used in staging, date of diagnosis, site of metastases, complications clinics.
Sociodemographic characteristics checklist	2022	Describe sociodemographic characteristics: age at diagnosis, race, education, family income, occupation, personal habits, family history, comorbidities, treatment funding (public or private), treatment institution (public, private or philanthropic).
Characteristics of systemic treatment checklist	2022	date of biopsy; dates, type and lines of drug treatment.

Trial Locations

Locations (16)

CINPAM - Centro Integrado de Pesquisa da Amazônia; 🇧🇷 Manaus, Amazonas, Brazil

Santa Casa de Misericórdia de Feira de Santana; 🇧🇷 Feira De Santana, Bahia, Brazil

NOB - Núcleo de Oncologia da Bahia (Oncoclínicas); 🇧🇷 Salvador, Bahia, Brazil

Oncocentro Ceará (Rede D'or); 🇧🇷 Fortaleza, Ceará, Brazil

Onco-Vida Instituto Especializado de Oncologia; 🇧🇷 Brasília, Distrito Federal, Brazil

Hospital Evangélico de Cachoeiro de Itapemirim - Centro de Pesquisas Clínicas em Oncologia (CPCO); 🇧🇷 Cachoeiro De Itapemirim, Espírito Santo, Brazil

Hospital do Câncer do Maranhão Dr. Tarquínio Lopes Filho; 🇧🇷 São Luís, Maranhão, Brazil

Clinica Prognóstica - Centro de Pesquisa Clínica Onconeo; 🇧🇷 Campo Grande, Mato Grosso Do Sul, Brazil

ICTR - Instituto do Câncer e Transplante de Curitiba; 🇧🇷 Curitiba, Paraná, Brazil

Hospital Napoleão Laureano; 🇧🇷 João Pessoa, Paraíba, Brazil

Scroll for more (6 remaining)